ibrutinib,rituximab
abbvie,janssen
[' ibru', 'cll', 'nhl', 'ritux', 'dlbcl']
triangle trial presented at #ash22 by martin dreyling. previously untreated #mcl patients received r-chop/r-dhap and:
1. asct + observation (w/ 58% receiving rituximab mx)
2. asct + 2 yrs ibrutinib mx (w/ 57% receiving rituximab)
3. 2 yrs ibrutinib mx (w/ 54% receiving rituximab) 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.